Patients with schizophrenia show low employment rates and low Quality of Life (QoL), and rehabilitation aims to maximise daily functioning, improve social interactions, and develop employment prospects. Evaluation of long-term treatment effectiveness should address these issues. Choice of medication can influence patient compliance and adverse experience of side effects may act as a barrier to rehabilitation. The Schizophrenia Trial of Aripiprazole (STAR), in which patients were randomised to receive 26 weeks of the atypical antipsychotic, aripiprazole (n=284) or standard of care medication (n=271) showed that aripiprazole demonstrated significantly better effectiveness in terms of Investigator Assessment Questionnaire (IAQ) total score. Like other atypical antipsychotic agents, aripiprazole shows a low rate of extrapyramidal adverse events. In addition, unlike the majority of other agents, aripiprazole treatment has a low risk of weight gain, translating into health-related QoL benefits. In summary, newer, atypical agents may improve efficacy, patient satisfaction, and aid long-term rehabilitation.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||The long term-maximising potential for rehabilitation in patients with schizophrenia|
|Citazione:||The long term-maximising potential for rehabilitation in patients with schizophrenia / Fagiolini, Andrea; Goracci, Arianna. - 17:Supplement 2(2007), pp. S123-S129. ((Intervento presentato al convegno EUROPEAN NEUROPSYCHOPHARMACOLOGY.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: